Literature DB >> 7563185

RET gene and its implications for cancer.

P J Goodfellow1, S A Wells.   

Abstract

The RET proto-oncogene encodes a protein receptor tyrosine kinase. RET mutations are associated with the dominantly inherited cancer syndromes multiple endocrine neoplasia (MEN) types 2A and 2B and familial medullary thyroid carcinoma (FMTC). In MEN 2A, MEN 2B, and FMTC, direct detection of RET mutations can be used to identify disease allele carriers prior to the development of clinically evident neoplasms. RET mutations are also associated with sporadic thyroid carcinomas. The effects of RET mutation on protein function have been investigated both in vivo and in vitro, and the study of RET has served to provide insights into the mechanisms of tumorigenesis in general.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7563185     DOI: 10.1093/jnci/87.20.1515

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  12 in total

1.  Mutation of RET proto-oncogene in Hirschsprung's disease and intestinal neuronal dysplasia.

Authors:  Jin-Fa Tou; Min-Ju Li; Tao Guan; Ji-Cheng Li; Xiong-Kai Zhu; Zhi-Gang Feng
Journal:  World J Gastroenterol       Date:  2006-02-21       Impact factor: 5.742

Review 2.  Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome).

Authors:  P J Morrison; N C Nevin
Journal:  J Med Genet       Date:  1996-09       Impact factor: 6.318

3.  Mechanism of extracellular Ca2+ receptor-stimulated hormone release from sheep thyroid parafollicular cells.

Authors:  D S McGehee; M Aldersberg; K P Liu; S Hsuing; M J Heath; H Tamir
Journal:  J Physiol       Date:  1997-07-01       Impact factor: 5.182

4.  Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.

Authors:  F M Michiels; S Chappuis; B Caillou; A Pasini; M Talbot; R Monier; G M Lenoir; J Feunteun; M Billaud
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

5.  RET polymorphisms might be the risk factors for thyroid cancer.

Authors:  Rui-Xue Huang; Fei Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.

Authors:  Valerie I Brown; Junjie Fang; Keith Alcorn; Rosalind Barr; Jenny M Kim; Robert Wasserman; Stephan A Grupp
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

Review 7.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 8.  RET and neuroendocrine tumors.

Authors:  Yoshiki Murakumo; Mayumi Jijiwa; Naoya Asai; Masatoshi Ichihara; Masahide Takahashi
Journal:  Pituitary       Date:  2006       Impact factor: 3.599

9.  Large-scale analysis of mutations in RET exon 16 in sporadic medullary thyroid carcinomas in Japan.

Authors:  T Takano; A Miyauchi; H Yoshida; Y Hasegawa; K Kuma; N Amino
Journal:  Jpn J Cancer Res       Date:  2001-06

10.  Novel point mutations and allele loss at the RET locus in sporadic medullary thyroid carcinomas.

Authors:  S Uchino; S Noguchi; M Adachi; M Sato; H Yamashita; S Watanabe; T Murakami; M Toda; N Murakami; H Yamashita
Journal:  Jpn J Cancer Res       Date:  1998-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.